0.9679

12.55% 0.1079

After Hours: 1.04 0.0721 +7.45%

Palatin Technologies Inc. (PTN)

Overview News Price History Option Chain Discussions Forecast Stock Split

Palatin Technologies Inc. stock is traded at $0.9679, with a volume of 2.95M. It is up +12.55% in the last 24 hours and up +5.87% over the past month. Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Previous Close:

$0.86

Open:

$0.93

24h Volume:

2.95M

Relative Volume:

7.32

Market Cap:

$22.70M

Revenue:

$7.10M

Net Income/Loss:

$-31.59M

P/E Ratio:

-0.3781

EPS:

-2.56

Net Cash Flow:

$-26.75M

1W Performance:

+10.62%

1M Performance:

+5.87%

6M Performance:

-48.52%

1Y Performance:

-60.81%

1-Day Range:

$0.9172

$1.20

1-Week Range:

$0.75

$1.20

52-Week Range:

$0.68

$5.65

Palatin Technologies Inc. Stock (PTN) Company Profile

Name

Palatin Technologies Inc.

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

609-495-2200

Address

Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ

Employee

Twitter

@PalatinTech

Next Earnings Date

2024-11-12

Latest SEC Filings

PTN's Discussions on Twitter

Compare PTN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTN Palatin Technologies Inc.	0.9679	22.70M	7.10M	-31.59M	-26.75M	-2.61
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-15	Reiterated	Canaccord Genuity	Buy
Jan-12-15	Reiterated	ROTH Capital	Buy
May-23-12	Initiated	Noble Financial	Buy
Jan-23-07	Initiated	Next Generation	Buy

Palatin Technologies Inc. Stock (PTN) Latest News

02:13 AM

Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World

02:13 AM

Dec 20, 2024

Palatin reports positive Phase 2b results in diabetic nephropathy - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

First Patient Dosed in Phase 2 Clinical Study of Palatin's Breme - GuruFocus.com

Dec 19, 2024

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PR Newswire

Dec 19, 2024

Dec 18, 2024

Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - MSN

Dec 18, 2024

Dec 17, 2024

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - The Eastern Progress Online

Dec 17, 2024

Dec 16, 2024

Palatin Technologies Secures $3.4M Through Strategic Warrant Exercise Deal, Issues New Warrants - StockTitan

Dec 16, 2024

Dec 12, 2024

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - The Eastern Progress Online

Dec 12, 2024

Dec 05, 2024

Palatin Technologies (BUE:PTN) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

Dec 04, 2024

Thinking about buying stock in MedAvail Holdings, Trio-Tech Inte - GuruFocus.com

Dec 04, 2024

Dec 01, 2024

PTN (Palatin Technologies) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

PTN (Palatin Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 26, 2024

Palatin Technologies stock stays Buy rated after completing Phase 2 enrollment in UC trial - Investing.com UK

Nov 26, 2024

Nov 25, 2024

Palatin Announces Completion of Patient Enrollment in Phase 2 St - GuruFocus.com

Nov 25, 2024

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis – Company AnnouncementFT.com - Financial Times

Nov 25, 2024

Palatin Completes Phase 2 Enrollment for Novel Ulcerative Colitis Pill, Data Due Q1 2025 - StockTitan

Nov 25, 2024

Nov 22, 2024

Palatin Technologies (FRA:PTN) Retained Earnings : €-405.08 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Palatin Technologies (FRA:PTN) Graham Number : €N/A (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Palatin Technologies (FRA:PTN) Float Percentage Of Total Sh - GuruFocus.com

Nov 21, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleco - GuruFocus.com

Nov 21, 2024

Nov 15, 2024

Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2024